Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

PURPOSE: Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or nonsquamous (CheckMate 057; ClinicalTrials....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Horn, Leora, Spigel, David R., Vokes, Everett E., Holgado, Esther, Ready, Neal, Steins, Martin, Poddubskaya, Elena, Borghaei, Hossein, Felip, Enriqueta, Paz-Ares, Luis, Pluzanski, Adam, Reckamp, Karen L., Burgio, Marco A., Kohlhäeufl, Martin, Waterhouse, David, Barlesi, Fabrice, Antonia, Scott, Arrieta, Oscar, Fayette, Jérôme, Crinò, Lucio, Rizvi, Naiyer, Reck, Martin, Hellmann, Matthew D., Geese, William J., Li, Ang, Blackwood-Chirchir, Anne, Healey, Diane, Brahmer, Julie, Eberhardt, Wilfried E.E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6075826/
https://ncbi.nlm.nih.gov/pubmed/29023213
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.74.3062
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados